J&J Recruits Patients for Phase 2 Trial of ITI-1284 for Generalized Anxiety Disorder
Phase 2 Trial Design and Development Timeline
Johnson & Johnson (JNJ) is conducting a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial (NCT06701903) of ITI-1284 monotherapy in patients with generalized anxiety disorder (GAD). The study, which began on November 21, 2024, will enroll adults who have not adequately responded to existing GAD treatments into groups receiving ITI-1284 10mg, 20mg, or placebo, and is expected to conclude on October 14, 2027. The primary efficacy endpoint is the change in the Hamilton Anxiety Rating Scale (HAM-A) at the six-week mark, which will determine the magnitude of effect across the two doses and the dose-response relationship, influencing the design of subsequent confirmatory trials.
Mechanism of Action and Formulation Differentiation
The generic name of ITI-1284 is deulumateperone, and it has not yet received a commercial brand name. It is a hydrogenated version of lumateperone, the active ingredient in the marketed drug Caplyta. ITI-1284 is being developed as an orally disintegrating sublingual tablet (ODT-SL) and utilizes a mechanism of action involving serotonin 5-HT2A, dopamine D2 receptors, and serotonin transporter, focusing on serotonin, dopamine, and glutamate modulation. The hydrogenation and sublingual formulation are strategic differentiators aimed at improving pharmacokinetics and dosing convenience, with compound patent protection extending until 2037.
Standard of Care and Competitive Landscape
Current pharmacological treatment for GAD centers on selective serotonin reuptake inhibitors (SSRIs) such as escitalopram (Lexapro), duloxetine (Cymbalta), and venlafaxine (Effexor XR), as well as serotonin-norepinephrine reuptake inhibitors (SNRIs), and the partial 5-HT1A agonist buspirone. While these drugs are already FDA-approved and commercially available, issues of insufficient response and tolerability remain. ITI-1284 must demonstrate additional efficacy as a monotherapy in patients who have failed existing treatments. A later-stage competitor is MM120 ODT, an LSD-based therapy from Definium Therapeutics (DNM), which has received FDA Breakthrough Therapy designation and is in Phase 3 trials for GAD, currently ahead in development speed.
Market Potential and Significance for J&J's Portfolio
There are approximately 6.8 million patients with GAD in the U.S., and the seven major markets (U.S., EU4, U.K., and Japan) are projected to reach a market size of about USD 2.0 billion in 2025. J&J acquired Intra-Cellular Therapies for approximately USD 14.5 billion on April 2, 2025, securing ITI-1284 and Caplyta, and ITCI shares were delisted from Nasdaq in the same month. ITI-1284 is currently a Phase 2 development asset with no prior FDA, EMA, or PMDA approvals or advisory committee (AdComm) reviews. The outcome of this trial will determine whether J&J's psychiatry franchise can establish a new growth pillar.
ITI-1284 is a Phase 2 asset targeting approximately 6.8 million U.S. patients and a 2025 seven-major-market size of USD 2.0 billion. In the short term, the six-week HAM-A improvement and safety profile of the 10mg and 20mg doses will be key criteria for advancing to Phase 3 trials. In the medium to long term, ITI-1284 could extend the serotonin-dopamine-glutamate modulation mechanism of the Caplyta family to GAD, thereby supporting the USD 14.5 billion acquisition value of J&J. Researchers must evaluate whether the hydrogenated sublingual ODT formulation can simultaneously improve efficacy and tolerability in patients who have had insufficient responses to existing SSRIs and SNRIs. The market will assess whether ITI-1284 can demonstrate differentiation compared to the Phase 3 MM120 ODT and currently marketed drugs such as Lexapro, Cymbalta, and Effexor XR, which will determine its commercial competitiveness.
Source: ClinicalTrials.gov (api_ct)